“ A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk’s weight-loss drug Wegovy last year , a powerful new tool to address record rates of pediatric obesity, according to data shared exclusively with Reuters.
In the first 10 months of 2023, 1,268 children ages 12 to 17 with an obesity diagnosis* started taking Wegovy , according to U.S. insurance claims data compiled by health technology company Komodo Health.” This psychological condition via framing the obesity epidemic as a “disease” with an accompanying “diagnosis” is not to be overlooked, as it provides valuable insight into how the pharmaceutical industry successfully parlays every physical, psychological, and social ailment into a medical diagnosis through a process called “medicalization” that I have previously described in great detail , which then opens the door for expensive, patented […]
Read the Whole Article From the Source: www.zerohedge.com
